Start with Parkinson disease, then reuse UniProt P80192 as the stable protein anchor across project notes and exports.
CHEMBL2872 Target Snapshot
Mitogen-activated protein kinase kinase kinase 9 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P80192. Start with Parkinson disease, then reuse UniProt P80192 as the stable protein anchor across project notes and exports.
Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease. 1 linked drug remains visible in the same block.
Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMitogen-activated protein kinase kinase kinase 9
Review this target as Mitogen-activated protein kinase kinase kinase 9, mapped to UniProt P80192. Sequence length is 1104 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase 9 as ChEMBL target CHEMBL2872, mapped to UniProt P80192. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 9 is the right protein anchor across sources, using UniProt P80192 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Parkinson disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Mitogen-activated protein kinase kinase kinase 9 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P80192 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Mitogen-activated protein kinase kinase kinase 9 |
| UniProt Accession | P80192 |
| Component Type | Protein |
| Sequence Length | 1104 aa |
Mitogen-activated protein kinase kinase kinase 9
How to read this target
Review this target as Mitogen-activated protein kinase kinase kinase 9, mapped to UniProt P80192. Sequence length is 1104 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Mitogen-activated protein kinase kinase kinase 9 shows clinical signal disease relevance led by Parkinson disease.
How to read disease relevance
Start review with Parkinson disease because it currently carries clinical signal support. Linked drugs include CEP-1347. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL388978 | 9.26 | IC50 | 0.544 | Preclinical |
| CHEMBL4465866 | 8.7 | Kd | 2.0 | Preclinical |
| CHEMBL4576489 | 8.52 | Kd | 3.0 | Preclinical |
| CHEMBL603469 | 8.46 | Kd | 3.5 | Clinical |
| CHEMBL4116008 | 8.4 | IC50 | 4.0 | Clinical |
| CHEMBL475251 | 8.37 | Kd | 4.3 | Clinical |
| CHEMBL388978 | 8.0 | Kd | 10.0 | Preclinical |
| CHEMBL4218417 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL5397819 | 7.85 | IC50 | 14.0 | Preclinical |
| CHEMBL5436267 | 7.85 | IC50 | 14.0 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 344 assays, 118 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 277 | 91 | 6.7 |
| assay format | 43 | 20 | 6.6 |
| cell-based format | 19 | 7 | 7.4 |
| subcellular format | 5 | 0 | — |
Functional — 2 assays, 2 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 2 | 6.8 |